{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:07:40Z","timestamp":1788584860478,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"Background<\/jats:title>Glycogen storage disease type 1b (GSD1b) is an ultra-rare autosomal recessive disorder, caused by mutations in SLC37A4<\/jats:italic> gene. Affected patients present with episodes of fasting hypoglycemia and lactic acidosis, hepatomegaly, growth retardation, hyperlipidemia and renal impairment. In addition, patients present neutropenia, neutrophil dysfunction and oral, and skin infections as well as a significant predisposition to develop inflammatory bowel disease (IBD). Low neutrophil counts and function is related to the toxic accumulation of 1,5-anhydroglucitol-6-phosphate (1,5-AG6P). Recently, several reports have shown that off-label treatment with empagliflozin (EMPA), an inhibitor of the renal glucose transporter SGLT2, decreased blood 1,5-anhydroglucitol (1,5-AG), and neutrophil 1,5-AG6P, thus resulting in a new therapeutic option for neutropenia and neutrophil dysfunction in patients.<\/jats:p><\/jats:sec>Methods<\/jats:title>Off-label treatment with EMPA was established in two GSD1b patients after signed informed consent. The patients were followed clinically. We monitored neutrophil counts and function, 1,5-AG levels in plasma and its renal clearance before and during EMPA treatment.<\/jats:p><\/jats:sec>Results<\/jats:title>A 17 year-old girl who had long standing oral ulcers and developed IBD, requiring systemic steroid and regular granulocyte colony-stimulating factor (GCSF) therapy and an 8 year-old boy who had steady non healing oral lesions were treated with empagliflozin during 18\u201324 months. Treatment led to increase of neutrophil counts and function with substantial clinical improvement. This included remission of IBD in the first patient which allowed to discontinue both GCSF and steroid therapy and resolution of oral lesions in both patients. The concentration of 1,5-AG in blood was greatly decreased within two weeks of treatment and remained stable thereafter.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Repurposing of empagliflozin to treat neutropenia in two GSD1b patients was safe and resulted in the urinary excretion of 1,5-AG, the normalization of neutrophil function, and a remarkable improvement of neutropenia-related clinical traits. We showed for the first time that empagliflozin increases concomitantly the renal clearance of both 1,5-anhydroglucitol and glucose in GSD1b patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.1071464","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T06:16:04Z","timestamp":1669184164000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients"],"prefix":"10.3389","volume":"10","author":[{"given":"Zufit","family":"Hexner-Erlichman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Veiga-da-Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Zehavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahava","family":"Vadasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi D.","family":"Sabag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Tatour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MCO.0000000000000181","article-title":"Hepatic glycogen storage disorders: what have we learned in recent years?","volume":"18","author":"Burda","year":"2015","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/TRD-160006","article-title":"Glyogen storage diseases: diagnosis, treatment and outcome","volume":"1","author":"Chen","year":"2016","journal-title":"Transl Sci Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1182\/blood-2013-05-502435","article-title":"Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib","volume":"123","author":"Sik Jun","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MOH.0000000000000474","article-title":"Neutropenia in glycogen storage disease ib (GSD Ib): outcomes for patients treated with granulocyte colony-stimulating factor (G-CSF)","volume":"26","author":"Dale","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.4049\/jimmunol.1601946","article-title":"Cutting edge: increased autoimmunity risk in glycogen storage disease type 1b is sssociated with a reduced engagement of glycolysis in T cells and an impaired regulatory T cell function","volume":"198","author":"Melis","year":"2017","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1067\/mpd.2000.105232","article-title":"Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I","volume":"137","author":"Visser","year":"2000","journal-title":"J Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.1816143116","article-title":"Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency","volume":"116","author":"Veiga-da-Cunha","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100813","DOI":"10.1016\/j.ymgmr.2021.100813","article-title":"The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb","volume":"29","author":"Raggi","year":"2021","journal-title":"Mol Genet Metab Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood.2019004465","article-title":"Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor","volume":"136","author":"Wortmann","year":"2020","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13052-021-01100-w","article-title":"Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report","volume":"47","author":"Rossi","year":"2021","journal-title":"Ital J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.gim.2022.04.001","article-title":"Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib","volume":"15","author":"Gr\u00fcnert","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/ped.14629","article-title":"Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib","volume":"63","author":"Mikami","year":"2021","journal-title":"Pediatr Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.5114\/aoms\/150029","article-title":"The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience","volume":"18","author":"Bidiuk","year":"2022","journal-title":"Arch Med Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.gim.2022.04.001","article-title":"Efficacy and safety of empagliflozin in glycogen storage disease type Ib: data from an international questionnaire","volume":"24","author":"Gr\u00fcnert","year":"2022","journal-title":"Genet Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/jimd.12509","article-title":"Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: impact of a mutation in SGLT5","volume":"45","author":"Boulanger","year":"2022","journal-title":"J Inherit Metab Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1515\/JPEM.2005.18.6.617","article-title":"Secondary diabetes mellitus: late complication of glycogen storage disease type 1b","volume":"18","author":"Spiegel","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/jmd2.12278","article-title":"Sodium-glucose cotransporter type 2 channel inhibitor: breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?","volume":"63","author":"Kaczor","year":"2022","journal-title":"JIMD Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13023-022-02345-2","article-title":"Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre","volume":"17","author":"Halligan","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabetes"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1071464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T06:16:05Z","timestamp":1669184165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1071464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":20,"alternative-id":["10.3389\/fped.2022.1071464"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1071464","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"article-number":"1071464"}}